User: Guest  Login
Title:

The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets.

Document type:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Author(s):
El, Kimberley; Douros, Jonathan D; Willard, Francis S; Novikoff, Aaron; Sargsyan, Ashot; Perez-Tilve, Diego; Wainscott, David B; Yang, Bin; Chen, Alex; Wothe, Donald; Coupland, Callum; Tschöp, Mattias H; Finan, Brian; D'Alessio, David A; Sloop, Kyle W; Müller, Timo D; Campbell, Jonathan E
Abstract:
The incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) mediate insulin responses that are proportionate to nutrient intake to facilitate glucose tolerance1. The GLP-1 receptor (GLP-1R) is an established drug target for the treatment of diabetes and obesity2, whereas the therapeutic potential of the GIP receptor (GIPR) is a subject of debate. Tirzepatide is an agonist at both the GIPR and GLP-1R and is a highly effective treatment for type 2 diabetes...     »
Journal title abbreviation:
Nat Metab
Year:
2023
Journal volume:
5
Journal issue:
6
Pages contribution:
945-954
Fulltext / DOI:
doi:10.1038/s42255-023-00811-0
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/37277609
TUM Institution:
Lehrstuhl für Stoffwechselerkrankungen (Prof. Tschöp)
 BibTeX